Chinook Therapeutics, Inc.(KDNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KDNY Chinook Therapeutics, Inc.

Halted 12-27 05:11:49 EST

40.39

+0.00

0.00%

High40.39	Low40.39	Vol0.00
Open40.39	D1 Closing40.39	Amplitude0.00%
Mkt Cap2.90B	Tradable Cap2.44B	Total Shares71.80M
T/O0.00	T/O Rate0.00%	Tradable Shares60.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"KDNY","market":"US","secType":"STK","nameCN":"Chinook Therapeutics, Inc.","latestPrice":40.39,"timestamp":1735246800000,"preClose":40.39,"halted":3,"volume":0,"delay":0,"floatShares":60387030,"shares":71804977,"eps":-3.516501,"marketStatus":"Halted","change":0,"latestTime":"12-27 05:11:49 EST","open":40.39,"high":40.39,"low":40.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.516501,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1735309800000},"marketStatusCode":1,"adr":0,"listingDate":1429070400000,"exchange":"NASDAQ","adjPreClose":40.39,"volumeRatio":1.1645755043015429,"impliedVol":0.098,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/KDNY/tweets","defaultTab":"tweets","newsList":[{"id":"2383688051","title":"Baillie Gifford Adjusts Portfolio in Q3 2023, NVIDIA Corp Sees Notable Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2383688051","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2383688051?lang=en_us&edition=fundamental","pubTime":"2023-11-14 05:05","pubTimestamp":1699909525,"startTime":"0","endTime":"0","summary":"Insight into Baillie Gifford 's Latest 13F Filings and Investment Strategy. GuruFocus has detected 5 Warning Signs with MELI.Baillie Gifford , a century-old investment management partnership, is renowned for its commitment to long-term, bottom-up investing and fundamental analysis. The firm's recent 13F filing for Q3 2023 reveals strategic adjustments in its portfolio, reflecting its focus on identifying companies with sustainable growth potential. Baillie Gifford 's investment approach, emphasizing professional excellence and client interests, has attracted a diverse international clientele, from pension funds to financial institutions across the globe.Baillie Gifford  expanded its portfolio with 8 new stocks in the third quarter of 2023. Noteworthy additions include:. Comfort Systems USA Inc , purchasing 1,187,920 shares, which now comprise 0.18% of the portfolio, valued at $202.43 million.ODDITY Tech Ltd , with 5,559,817 shares, making up about 0.14% of the portfolio, totaling $157.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gMhK7EJ1jmKFKSxAEg9pHg--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/695ce32b8e47b20b9dbeed1d6d0d7a9c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gMhK7EJ1jmKFKSxAEg9pHg--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/695ce32b8e47b20b9dbeed1d6d0d7a9c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/baillie-gifford-adjusts-portfolio-q3-210525027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","IE00BJJMRX11.SGD","KDNY","QLD","BK4511","LU0516422440.USD","LU0528227936.USD","ILMN","NQmain","FIX","FUTU","BK4559","IE00B775SV38.USD","IE00BJTD4N35.SGD","ODD","IE00B3S45H60.SGD","BK4538","IE00B19Z4B17.USD","LU1804176565.USD","LU0889565833.HKD","LU0354030438.USD","TQQQ","BK4558","BK4535","IE00BJTD4V19.USD","LU2357305700.SGD","LU1551013425.SGD","NVDA","HDB","LU0211327993.USD","AMZN","BK4554","MELI","BK4550","GB00BDT5M118.USD","QQQ","SQQQ","BK4553","TSLA","PDD","FN","MRNA","BK4555","MNQmain","LU2264538146.SGD","PSQ","LU0354030511.USD","LU1551013342.USD","LU0079474960.USD","QID"],"gpt_icon":0},{"id":"2361781836","title":"Altium Capital Management LP Acquires New Stake in Alimera Sciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2361781836","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2361781836?lang=en_us&edition=fundamental","pubTime":"2023-08-23 21:02","pubTimestamp":1692795761,"startTime":"0","endTime":"0","summary":"Altium Capital Management LP, a New York-based investment firm, recently made a significant move in the stock market by acquiring a new stake in Alimera Sciences Inc. This article provides an in-depth analysis of the transaction, the profiles of both entities, and the potential implications of this strategic move.On August 15, 2023, Altium Capital Management LP purchased 2,984,803 shares of Alimera Sciences Inc at a price of $3.57 per share. This acquisition had a 7.46% impact on the firm's portfolio, making it a significant transaction. Following this purchase, Altium Capital Management LP now holds a total of 2,984,803 shares in Alimera Sciences Inc, representing 5.70% of the company's total shares.Alimera Sciences Inc's financial health is evaluated using several metrics. The company's Financial Strength is ranked 3/10, its Profitability Rank is 2/10, and its Growth Rank is 2/10. The company's Piotroski F-Score is 3, indicating a poor financial situation. Its Altman Z score is -2.50","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/yXHYYw.e0qOcnAvZjcdMZQ--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/812a0527371141a498c1403e2ac15372","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/yXHYYw.e0qOcnAvZjcdMZQ--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/812a0527371141a498c1403e2ac15372"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/altium-capital-management-lp-acquires-130241025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","SQQQ","ADMA","ALIM","BK4007","BK4585","QQQ","ATXS","MNQmain","XENE","ROE",".IXIC","NQmain","QID","BK4139","IMGN","KDNY","PSQ","QLD"],"gpt_icon":0},{"id":"2358944980","title":"Bragar Eagel & Squire, P.C. Is Investigating JinkoSolar, Integra, Chinook, and Comerica and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2358944980","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2358944980?lang=en_us&edition=fundamental","pubTime":"2023-08-12 09:00","pubTimestamp":1691802000,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against JinkoSolar Holding Co., Ltd. (NY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22035896","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["SQQQ","PSQ","QLD","BK4082","BK4589","MNQmain","QID",".IXIC","BK4211","BK4141","BK4519","KDNY","BK4526","CMA","BK4588","BK4207","BK4585","JKS","NQmain","ISBC","TQQQ","BK4139","QQQ","IART"],"gpt_icon":0},{"id":"2358651980","title":"BRIEF-Novartis Completes Acquisition Of Chinook Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2358651980","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2358651980?lang=en_us&edition=fundamental","pubTime":"2023-08-11 23:31","pubTimestamp":1691767881,"startTime":"0","endTime":"0","summary":"Aug 11 (Reuters) - Novartis AG   :   * NOVARTIS COMPLETES ACQUISITION OF CHINOOK THERAPEUTICSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KDNY"],"gpt_icon":0},{"id":"2358331587","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2358331587","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2358331587?lang=en_us&edition=fundamental","pubTime":"2023-08-09 18:00","pubTimestamp":1691575200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Alpha and Omg Sem                               4Q       .02    4:01 PM. Arhaus Inc. Class A                             2Q       .26    6:30 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLND","G","AVDL","HCCI","BDTX","BERY","CGC","CARG","FSM","AVNS","ERF","CGEM","EVRI","JACK","CYRX","CANO","CCAP","BLDE","AVID","CIB","FTCI","INFN","SKIN","AVPT","KDNY","BLTE","INSW","CNNE","FEMY","ASMB","ESEA","KRT","NOTE","BKSY","BLBD","AVTA","FTHM","JAZZ","KORE","ADMA","CYCC","ILMN","HLTH","IONS","INSE","INO","GDRX","BLDP","BCDA","BOXL"],"gpt_icon":0},{"id":"2357347753","title":"Bragar Eagel & Squire, P.C. Is Investigating JinkoSolar, Integra, Chinook, and Comerica and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2357347753","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2357347753?lang=en_us&edition=fundamental","pubTime":"2023-08-07 09:00","pubTimestamp":1691370000,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug. 06, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against JinkoSolar Holding Co., Ltd. (NY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22002545","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["JKS","BK4211","BK4589","BK4588","NQmain","KDNY","QQQ","BK4139","BK4519","MNQmain","QID","TQQQ","BK4207","CMA",".IXIC","BK4082","QLD","BK4585","BK4141","BK4526","ISBC","PSQ","IART","SQQQ"],"gpt_icon":0},{"id":"2357473783","title":"2023 shaping up to be biggest year for biopharma M&A since pandemic","url":"https://stock-news.laohu8.com/highlight/detail?id=2357473783","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2357473783?lang=en_us&edition=fundamental","pubTime":"2023-08-07 03:35","pubTimestamp":1691350500,"startTime":"0","endTime":"0","summary":"The IPO market may still be frigid, but 2023 is shaping up to be the biggest year for biopharma M&A since the pandemic, despite rising capital costs and increased scrutiny by antitrust regulators. The","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/3997958-2023-shaping-up-to-be-biggest-year-for-biopharma-ma-since-pandemic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QID","SG9999002232.USD","KVUE","SGEN","IE0002141913.USD","BK4548","BK4139","NQmain","KDNY","LU0058720904.USD","LU0234570918.USD","LU1023059063.AUD","LU1093756168.USD","LU2242652126.USD","PFE","IE00BLSP4452.SGD","BK4578","LU0965509283.SGD","LU1571399168.USD","QQQ","RETA","HZNP","MNQmain","LU1093756325.SGD","LU2361044949.HKD","BK4516","LU0889565916.HKD","SG9999001176.USD","NVS","LU0320765992.SGD","BK4581","IE00B19Z9Z06.USD","LU2106854487.HKD","SQQQ","QLD","TQQQ","AMGN","ILMN","LU0122379950.USD","BK4568","PSQ","BIIB","KVUE.WI","LU0234572021.USD","LU0861579265.USD","IE0009355771.USD","LU2361044865.SGD","MRK",".IXIC","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2356489126","title":"Wall Street Analysts Are Downgrading These 10 Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2356489126","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2356489126?lang=en_us&edition=fundamental","pubTime":"2023-08-03 23:48","pubTimestamp":1691077735,"startTime":"0","endTime":"0","summary":"In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visitAnalysts Are Downgrading These 5 Stocks.On the banking side, the swift collapse of Silicon Valley Bank earlier this year revealed a concerning truth: certain U.S. banks aren't adequately prepared to borrow from the Federal Reserve in times of need. This issue is particularly pronounced among smaller banks in the nation. For instance, Silicon Valley Bank's downfall was partially attributed to its lack of readiness and failure to test its access to the \"discount window,\" which is the Federal Reserve's channel for emergency loans. The fallout from Silicon Valley Bank's situation highlighted the importance of being prepared to borrow from the Federal Reserve in times of financial distress. The process involves filing paperwork, collateral posting, and ideally, conducting regular trial runs. Although banks aren't obligated to disclose whether","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GhlRVcMNkK5GKtUhvoRC0g--~B/aD0yODgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/89e1f430fe28c1b8a95ed15a5f2121e9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GhlRVcMNkK5GKtUhvoRC0g--~B/aD0yODgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/89e1f430fe28c1b8a95ed15a5f2121e9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-downgrading-10-154855746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SOFI","BK4551","SQQQ","LU2552382058.USD","LU1720051017.SGD","ZI","KDNY","BK4209","LU1861220033.SGD","BK4549","LU1720051108.HKD","LU2357305700.SGD","BK4098","BLMN","TQQQ","BK4109",".IXIC","BK4183","BK4139","CNI","BK4504","BK4548","EL","LU2552382132.HKD","QID","BK4533","BK4077","NQmain","BK4558","EMN","BK4016","MNQmain","LU1548497426.USD","BK4173","PSQ","BRO","QLD","BK4535","LU2552382215.SGD","QQQ","BK4585","BK4588","BK4166","LU1861215975.USD"],"gpt_icon":0},{"id":"2356950741","title":"Bragar Eagel & Squire, P.C. Is Investigating JinkoSolar, Integra, Chinook, and Comerica and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2356950741","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2356950741?lang=en_us&edition=fundamental","pubTime":"2023-08-01 09:00","pubTimestamp":1690851600,"startTime":"0","endTime":"0","summary":"NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against JinkoSolar Holding Co., Ltd. (NY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=21973519","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["KDNY","BK4211","SQQQ","BK4589","BK4588","ISBC","NQmain","BK4519","MNQmain","IART","BK4139","BK4526","QID","QQQ","BK4082","BK4141","BK4207","CMA","BK4585","PSQ","QLD","JKS","TQQQ",".IXIC"],"gpt_icon":0},{"id":"2354632519","title":"BRIEF-Chinook Therapeutics Announces First Patient Enrolled In Phase 3 Of Zigakibart","url":"https://stock-news.laohu8.com/highlight/detail?id=2354632519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2354632519?lang=en_us&edition=fundamental","pubTime":"2023-07-28 23:25","pubTimestamp":1690557941,"startTime":"0","endTime":"0","summary":"July 28 (Reuters) - Chinook Therapeutics Inc   :   * CHINOOK THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PIVOTAL PHASE 3 BEYOND STUDY OF ZIGAKIBART (BION-1301) FOR PATIENTS WITH IGA NEPHROPATHYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KDNY"],"gpt_icon":0},{"id":"2354446638","title":"Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2354446638","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2354446638?lang=en_us&edition=fundamental","pubTime":"2023-07-28 20:00","pubTimestamp":1690545600,"startTime":"0","endTime":"0","summary":"SEATTLE, July 28, 2023  -- Chinook Therapeutics, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy  has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart , a potentially disease-modifying anti-APRIL monoclonal antibody.The primary efficacy endpoint of the BEYOND study is to evaluate the effect of zigakibart versus placebo on proteinuria as measured by change in urine protein to creatinine ratio  from baseline to 40 weeks. Secondary and exploratory objectives include evaluating change in eGFR from baseline to week 104; composite clinical outcome of 30% or 40% reduction in eGFR, eGFR < 15 mL/min/1.73m2 or dialysis, kidney transplantation or all-cause mortality; sa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xhf5U8pmb_dgG95jfuo8Jw--~B/aD00MDA7dz03MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/ddcae3626ec3422b7182131a6b66ba84","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xhf5U8pmb_dgG95jfuo8Jw--~B/aD00MDA7dz03MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/ddcae3626ec3422b7182131a6b66ba84"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chinook-therapeutics-announces-first-patient-120000459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","KDNY"],"gpt_icon":0},{"id":"2354855240","title":"Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, DLocal, and Comerica and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2354855240","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2354855240?lang=en_us&edition=fundamental","pubTime":"2023-07-27 09:00","pubTimestamp":1690419600,"startTime":"0","endTime":"0","summary":"NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=21953142","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4106","BK4589","DLO","BK4082","BK4139","BK4563","BK4539","TQQQ","SQQQ","BK4207","ISBC","IART","BK4588","NQmain","KDNY",".IXIC","CMA","BK4585","MNQmain","QQQ","BK4211","QID","BK4227","PSQ","QLD"],"gpt_icon":0},{"id":"2353850402","title":"Bragar Eagel & Squire, P.C. Is Investigating Chinook, Comerica, Advance Auto Parts, and EPAM and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2353850402","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2353850402?lang=en_us&edition=fundamental","pubTime":"2023-07-22 09:00","pubTimestamp":1689987600,"startTime":"0","endTime":"0","summary":"NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Chinook Therapeutics, Inc. (NASD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=21935294","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4139","BK4585","BK4207","BK4134","EPAM","KDNY","LU2045819591.USD","LU2125910500.SGD","BK4214","BK4589","ISBC","BK4588","BK4566","BK4211","AAP","CMA"],"gpt_icon":0},{"id":"2352089192","title":"Bragar Eagel & Squire, P.C. Is Investigating Chinook, Comerica, Advance Auto Parts, and EPAM and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2352089192","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2352089192?lang=en_us&edition=fundamental","pubTime":"2023-07-17 08:56","pubTimestamp":1689555360,"startTime":"0","endTime":"0","summary":"NEW YORK, July 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Chinook Therapeutics, Inc. (NASD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=21911443","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4588","CMA","AAP","EPAM","BK4211","BK4139","KDNY","LU2045819591.USD","LU2125910500.SGD","ISBC","BK4589","BK4134","BK4207","BK4585","BK4566","BK4214"],"gpt_icon":0},{"id":"2350195176","title":"Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, DLocal, and Comerica and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2350195176","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2350195176?lang=en_us&edition=fundamental","pubTime":"2023-07-11 09:00","pubTimestamp":1689037200,"startTime":"0","endTime":"0","summary":"NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=21893148","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4106","BK4589","DLO","BK4082","BK4139","BK4563","BK4539","TQQQ","SQQQ","BK4207","ISBC","IART","BK4588","NQmain","KDNY",".IXIC","CMA","BK4585","MNQmain","QQQ","BK4211","QID","BK4227","PSQ","QLD"],"gpt_icon":0},{"id":"2349619577","title":"Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, DLocal, and Comerica and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2349619577","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2349619577?lang=en_us&edition=fundamental","pubTime":"2023-07-06 09:00","pubTimestamp":1688605200,"startTime":"0","endTime":"0","summary":"NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=21878904","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4539","SQQQ","KDNY","BK4227","BK4589","DLO","BK4082","TQQQ",".IXIC","BK4139","BK4106","BK4563","QID","IART","NQmain","BK4207","MNQmain","BK4211","ISBC","PSQ","CMA","QLD","QQQ","BK4585","BK4588"],"gpt_icon":0},{"id":"2349563283","title":"ANI Pharmaceuticals Is Undervalued When Considering Their Unadvertised Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2349563283","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2349563283?lang=en_us&edition=fundamental","pubTime":"2023-07-05 12:51","pubTimestamp":1688532714,"startTime":"0","endTime":"0","summary":"iQoncept/iStock via Getty ImagesANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality br","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163421714/image_1163421714.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163421714/image_1163421714.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4615190-ani-pharmaceuticals-undervalued-considering-unadvertised-pipeline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00BLSP4452.SGD","BK4578","BK4534","BK4143","ETON","IE0002270589.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","MNK","LU1989764748.USD","SG9999001176.SGD","SGXZ57979304.SGD","SG9999002224.SGD","SG9999011175.SGD","BK4007","LU0289739699.SGD","LU1023059063.AUD","PFE","LU1989764664.SGD","BK4533","ANIP","LU0456855351.SGD","VEEV","LU0058720904.USD","IE00B2B36J28.USD","BK4588","BK4550","SG9999001176.USD","BK4167","LU1066051498.USD","IE0002141913.USD","BK4585","BK4504","ARC","NVS","LU1066053197.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4139","BK4581","BK4528","KDNY","LU0234572021.USD","SG9999002232.USD","IE0009355771.USD","SG9999013999.USD","LU0211331839.USD","SG9999003800.SGD","IE00BJJMRZ35.SGD","LU0122379950.USD"],"gpt_icon":0},{"id":"2348501731","title":"Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2348501731","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2348501731?lang=en_us&edition=fundamental","pubTime":"2023-07-04 21:42","pubTimestamp":1688478134,"startTime":"0","endTime":"0","summary":"libre de droit Key update: ERA 36 weeks presentation On June 17th, during the late-breaking discourse at the 60th European Renal Association Congress, Vera Therapeutics (NASDAQ:VERA) unveiled the comp","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1458871453/image_1458871453.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1458871453/image_1458871453.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4615131-vera-new-kidney-data-potential-next-big-pharma-m-and-a-target","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4114","BK4578","IE00BJT1NW94.SGD","LU0211331839.USD","LU1244550577.SGD","VERA","BK4504","BK4533","IE00B2B36J28.USD","BK4585","BK4139","LU1244550494.USD","BK4539","BK4588","IE0009355771.USD","NVS","LU0823411888.USD","LU1244550221.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4155","IE0002141913.USD","BK4532","KDNY","TGT","BK4007"],"gpt_icon":0},{"id":"2348373074","title":"Bragar Eagel & Squire, P.C. Is Investigating Chinook, DLocal, Comerica, and Advanced Auto Parts and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2348373074","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2348373074?lang=en_us&edition=fundamental","pubTime":"2023-07-01 09:00","pubTimestamp":1688173200,"startTime":"0","endTime":"0","summary":"NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Chinook Therapeutics, Inc. (NASD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=21867279","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4139","BK4207","NQmain","QID","QLD",".IXIC","BK4563","BK4214","SQQQ","DLO","BK4589","BK4588","AAP","BK4539","BK4211","TQQQ","BK4227","QQQ","ISBC","PSQ","CMA","BK4106","BK4585","KDNY","MNQmain"],"gpt_icon":0},{"id":"2347559743","title":"Activision Calls Could Pop But...","url":"https://stock-news.laohu8.com/highlight/detail?id=2347559743","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2347559743?lang=en_us&edition=fundamental","pubTime":"2023-06-30 00:00","pubTimestamp":1688054400,"startTime":"0","endTime":"0","summary":"Special purpose acquisition companies SPAC IPOs or SPACs trading at a discount to their cash in trust before their redemption deadlines are great places for principal protection. AltC Acquisition Corp.  IPOed at $10 . I can redeem it for around $10.28 per share in cash or sell it in the market for a current price of $10.54 or wait to see if they find a way to supply the limitless demand for AI-themed investments with a deal that causes the price to roar. Sam Altman, CEO of OpenAI, is AltC's executive officer and director. The upside is highly speculative but the downside from the last price is certain and limited. The downside from the IPO was certain and zero . Merger arbitrage Merger arb can offer principal protection as well. I own a substantial stake in Chinook Therapeutics  which is in the process of getting bought by Novartis . The deal requires HSR antitrust approval as well as KDNY shareholder approval. There are no legitimate antitrust problems as KDNY doesn't directly overlap","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/170825634/image_170825634.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/170825634/image_170825634.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4614403-activision-calls-could-pop-but","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00BJJMRX11.SGD","LU0127658192.USD","KDNY","BK4566","LU0109392836.USD","ATVI","BK4567","LU0170899867.USD","LU0211331839.USD","LU0198837287.USD","BK4554","ALCC","BK4129","IE0034235188.USD","LU0256863811.USD","BK4533","LU0175139822.USD","IE00BJTD4N35.SGD","VATE","BK4550","BK4516","BK4548","IE0004445015.USD","BK4539","IE00B775SV38.USD","LU0011850046.USD","LU1093756325.SGD","BK4535","IE00BJJMRY28.SGD","IE00BKVL7J92.USD","MSFT","IE0009355771.USD","IE00B1XK9C88.USD","BK4097","LU0056508442.USD","NVS","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0171293334.USD","BK4538","IE0002141913.USD","LU0320765489.SGD","LU0097036916.USD","BK4532","LU0149725797.USD","LU0079474960.USD","BK4534","BK4085","IE00BJTD4V19.USD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinooktx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0523},{"period":"6month","weight":0.105},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.2652}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.050571},{"month":2,"riseRate":0.5,"avgChangeRate":0.153158},{"month":3,"riseRate":0.375,"avgChangeRate":0.053741},{"month":4,"riseRate":0.5,"avgChangeRate":-0.046054},{"month":5,"riseRate":0.666667,"avgChangeRate":0.077697},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.052217},{"month":7,"riseRate":0.555556,"avgChangeRate":0.022688},{"month":8,"riseRate":0.555556,"avgChangeRate":0.015005},{"month":9,"riseRate":0.125,"avgChangeRate":-0.089457},{"month":10,"riseRate":0.5,"avgChangeRate":-0.047181},{"month":11,"riseRate":0.875,"avgChangeRate":0.086951},{"month":12,"riseRate":0.444444,"avgChangeRate":0.007063}],"exchange":"NASDAQ","name":"Chinook Therapeutics, Inc.","nameEN":"Chinook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Chinook Therapeutics, Inc.(KDNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Chinook Therapeutics, Inc.(KDNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Chinook Therapeutics, Inc.,KDNY,Chinook Therapeutics, Inc.股票,Chinook Therapeutics, Inc.股票老虎,Chinook Therapeutics, Inc.股票老虎国际,Chinook Therapeutics, Inc.行情,Chinook Therapeutics, Inc.股票行情,Chinook Therapeutics, Inc.股价,Chinook Therapeutics, Inc.股市,Chinook Therapeutics, Inc.股票价格,Chinook Therapeutics, Inc.股票交易,Chinook Therapeutics, Inc.股票购买,Chinook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Chinook Therapeutics, Inc.(KDNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Chinook Therapeutics, Inc.(KDNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction